The estimated Net Worth of Magda Marquet is at least 217 千$ dollars as of 15 June 2024. Magda Marquet owns over 3,900 units of Arcturus Therapeutics Inc stock worth over 81,822$ and over the last 6 years he sold ARCT stock worth over 0$. In addition, he makes 135,006$ as Independent Director at Arcturus Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Magda Marquet ARCT stock SEC Form 4 insiders trading
Magda has made over 4 trades of the Arcturus Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 3,900 units of ARCT stock worth 81,822$ on 15 June 2024.
The largest trade he's ever made was exercising 3,900 units of Arcturus Therapeutics Inc stock on 15 June 2024 worth over 81,822$. On average, Magda trades about 680 units every 102 days since 2019. As of 15 June 2024 he still owns at least 3,900 units of Arcturus Therapeutics Inc stock.
You can see the complete history of Magda Marquet stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Magda Marquet biography
Dr. Magda Marquet Ph.D. serves as Independent Director of the Company. Dr. Marquet has served as co-founder and co-chief executive officer of ALMA Life Sciences LLC, an early-stage healthcare investment firm, since 2013. Dr. Marquet also has been a co-founder of AltheaDx, a biotechnology company, since 2009. Dr. Marquet previously served as the co-founder and chairman of Althea Technologies, a biotechnology company, from 2009 to 2019, and previously served as its co-president and co-chief executive officer from 1998 to 2009. Prior to starting Althea Technologies, Dr. Marquet held several positions in product development and pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals. Dr. Marquet has served on the board of directors of Pfenex, a biotechnology company, since 2019 as well as several private company boards. Dr. Marquet holds a Ph.D. in biochemical engineering from INSA/University of Toulouse, France. Dr. Marquet is nominated for re-election on our Board because of her significant experience as an executive and director of a number of companies in the life sciences sector, and because of her management and clinical expertise.
What is the salary of Magda Marquet?
As the Independent Director of Arcturus Therapeutics Inc, the total compensation of Magda Marquet at Arcturus Therapeutics Inc is 135,006$. There are 11 executives at Arcturus Therapeutics Inc getting paid more, with Andrew Sassine having the highest compensation of 1,326,880$.
How old is Magda Marquet?
Magda Marquet is 61, he's been the Independent Director of Arcturus Therapeutics Inc since 2018. There are 2 older and 9 younger executives at Arcturus Therapeutics Inc. The oldest executive at Arcturus Therapeutics Holdings Inc is Edward Holmes, 79, who is the Independent Director.
What's Magda Marquet's mailing address?
Magda's mailing address filed with the SEC is C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO, CA, 92121.
Insiders trading at Arcturus Therapeutics Inc
Over the last 12 years, insiders at Arcturus Therapeutics Inc have traded over 137,035,874$ worth of Arcturus Therapeutics Inc stock and bought 56,234 units worth 767,374$ . The most active insiders traders include William M Kahane、Nicholas S Schorsch、Peter C Farrell. On average, Arcturus Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of 1,034,818$. The most recent stock trade was executed by Jing L. Marantz on 14 June 2024, trading 3,131 units of ARCT stock currently worth 65,688$.
What does Arcturus Therapeutics Inc do?
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
What does Arcturus Therapeutics Inc's logo look like?
Complete history of Magda Marquet stock trades at AnaptysBio Inc、Pfenex、Arcturus Therapeutics Inc
Arcturus Therapeutics Inc executives and stock owners
Arcturus Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Andrew Sassine,
Chief Financial Officer, Director -
Joseph Payne,
President, Chief Executive Officer, Director -
Joseph E. Payne M.Sc.,
Founder, Pres, CEO & Director -
Dr. Steven George Hughes M.B.A., M.D.,
Chief Medical Officer -
Dr. Padmanabh Chivukula,
Founder, Chief Scientific Officer, COO & Sec. -
Andrew H. Sassine,
CFO & Director -
Padmanabh Chivukula,
Chief Operating Officer, Chief Scientific Officer -
Lance Kurata,
Chief Legal Officer -
Karah Parschauer,
Director -
Edward Holmes,
Independent Director -
Peter Farrell,
Independent Chairman of the Board -
Magda Marquet,
Independent Director -
James Barlow,
Independent Director -
Steven Hughes,
Chief Development Officer -
Dr. Nirdosh Jagota Ph.D.,
Exec. VP & Chief Regulatory Officer -
Kevin T. Skol,
Sr. VP of Bus. Devel. & Alliance Management -
Neda Safarzadeh,
Sr. Director and Head of Investor Relations/PR & Marketing -
Dr. Dushyant B. Varshney Ph.D.,
Exec. VP & Chief Technology Officer -
Keith C. Kummerfeld CPA,
VP of Fin. & Corp. Controller -
Capital Group, Lpluxor Capi...,
-
William G Stanley,
Director -
Leslie D Michelson,
Director -
Susan E Manning,
See Remarks -
William M Kahane,
President and CEO -
Brian D Jones,
CFO and Treasurer -
Nicholas S Schorsch,
Director -
Robert Burns,
Director -
Pad Chivukula,
Chief Scientific Officer & COO -
Keith C Kummerfeld,
See Remarks -
Andy Sassine,
Chief Financial Officer -
Lance Kurata,
Chief Legal Officer -
Pharmaceutical Inc. Ultragenyx,
Director -
Jing L. Marantz,
Director -
John Markels,
Director -
Moncef Slaoui,
Director